These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 24857420

  • 1. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review.
    Schmulson M, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA.
    Rev Gastroenterol Mex; 2014; 79(2):96-134. PubMed ID: 24857420
    [Abstract] [Full Text] [Related]

  • 2. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
    Moraru IG, Moraru AG, Andrei M, Iordache T, Drug V, Diculescu M, Portincasa P, Dumitrascu DL.
    Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
    [Abstract] [Full Text] [Related]

  • 3. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
    Jin Y, Ren X, Li G, Li Y, Zhang L, Wang H, Qian W, Hou X.
    J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
    [Abstract] [Full Text] [Related]

  • 4. Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?
    Stoicescu A, Andrei M, Becheanu G, Stoicescu M, Nicolaie T, Diculescu M.
    Rev Med Chir Soc Med Nat Iasi; 2012 Feb; 116(3):766-72. PubMed ID: 23272525
    [Abstract] [Full Text] [Related]

  • 5. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
    Aziz I, Törnblom H, Simrén M.
    Curr Opin Gastroenterol; 2017 May; 33(3):196-202. PubMed ID: 28257307
    [Abstract] [Full Text] [Related]

  • 6. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A.
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [Abstract] [Full Text] [Related]

  • 7. [Microbiota and irritable bowel syndrome].
    Ducrotté P.
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S52-6. PubMed ID: 20889005
    [Abstract] [Full Text] [Related]

  • 8. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
    Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A.
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
    [Abstract] [Full Text] [Related]

  • 9. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.
    Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW.
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1689-94. PubMed ID: 19120860
    [Abstract] [Full Text] [Related]

  • 10. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets.
    Dahlqvist G, Piessevaux H.
    Acta Gastroenterol Belg; 2011 Sep; 74(3):375-80. PubMed ID: 22103040
    [Abstract] [Full Text] [Related]

  • 11. [Estimation of small intestinal bacterial overgrowth in patients with constipation and diarrhea irritable bowel syndrome].
    Łokieć K, Klupińska G, Walecka-Kapica E, Błońska A.
    Pol Merkur Lekarski; 2014 May; 36(215):307-10. PubMed ID: 24964506
    [Abstract] [Full Text] [Related]

  • 12. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome.
    Lin HC.
    JAMA; 2004 Aug 18; 292(7):852-8. PubMed ID: 15316000
    [Abstract] [Full Text] [Related]

  • 13. A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome.
    Ghoshal UC, Nehra A, Mathur A, Rai S.
    J Gastroenterol Hepatol; 2020 Jun 18; 35(6):922-931. PubMed ID: 31750966
    [Abstract] [Full Text] [Related]

  • 14. Reduced interstitial cells of Cajal and increased intraepithelial lymphocytes are associated with development of small intestinal bacterial overgrowth in post-infectious IBS mouse model.
    Chen B, Zhu S, Du L, He H, Kim JJ, Dai N.
    Scand J Gastroenterol; 2017 Oct 18; 52(10):1065-1071. PubMed ID: 28679338
    [Abstract] [Full Text] [Related]

  • 15. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective.
    Spiegel BM.
    Clin Gastroenterol Hepatol; 2011 Jun 18; 9(6):461-9; quiz e59. PubMed ID: 21397724
    [Abstract] [Full Text] [Related]

  • 16. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.
    Ghoshal UC, Shukla R, Ghoshal U.
    Gut Liver; 2017 Mar 15; 11(2):196-208. PubMed ID: 28274108
    [Abstract] [Full Text] [Related]

  • 17. [Irritable Bowel Syndrome, Emotion Regulation, and Gut Microbiota].
    Fukudo S.
    Brain Nerve; 2016 Jun 15; 68(6):607-15. PubMed ID: 27279158
    [Abstract] [Full Text] [Related]

  • 18. Rifaximin treatment for symptoms of irritable bowel syndrome.
    Fumi AL, Trexler K.
    Ann Pharmacother; 2008 Mar 15; 42(3):408-12. PubMed ID: 18303148
    [Abstract] [Full Text] [Related]

  • 19. Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome.
    Yang M, Zhang L, Hong G, Li Y, Li G, Qian W, Xiong H, Bai T, Song J, Hou X.
    J Gastroenterol Hepatol; 2020 May 15; 35(5):795-805. PubMed ID: 31674052
    [Abstract] [Full Text] [Related]

  • 20. Is irritable bowel syndrome an infectious disease?
    Thompson JR.
    World J Gastroenterol; 2016 Jan 28; 22(4):1331-4. PubMed ID: 26819502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.